Form 4: Apogee Therapeutics CMO Executes Stock Option Exercise

Chief Medical Officer Carl Dambkowski exercised options and sold shares of Apogee Therapeutics under a 10b5-1 trading plan.

Summary

• Chief Medical Officer Carl Dambkowski exercised options to acquire 4,125 shares of common stock at a price of $22.86 per share.
• Following the exercise, the reporting person sold 5,500 shares of common stock at an average price of $78.71 per share.
• The transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on September 22, 2025.
• The reporting person maintains a beneficial ownership of 205,648 shares of common stock following these transactions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed under a pre-planned 10b5-1 arrangement and does not necessarily reflect a change in the executive's outlook on the company.

Positives

• The executive continues to hold a significant position of 205,648 shares, indicating ongoing alignment with shareholder interests.

Negatives

• The transaction represents a divestment of shares by a key member of the executive leadership team.

Risks

• Future share price volatility may impact the value of remaining holdings.
• Reliance on Rule 10b5-1 plans does not eliminate the potential for negative market perception regarding insider selling.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via pre-arranged 10b5-1 plans is a standard practice for executives in the biotechnology sector to manage personal liquidity and diversify portfolios, and is generally viewed as neutral by the market.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate officers to avoid allegations of insider trading.
• The scale of the sale relative to the total holdings is consistent with typical executive equity management patterns in mid-cap biotech firms.

Stakeholder Impact

• Shareholders should note the reduction in insider holdings, though the use of a 10b5-1 plan mitigates concerns regarding non-public information usage.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Apogee Therapeutics, APGE, Insider Trading, Form 4, Biotech, Executive Compensation